Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 34 Neoplasm Metastasis 5 Breast Neoplasms 4 Prostate Carcinoma Metastatic to the Bone 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer 2 Hormone Refractory Prostate Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Prostate Cancer Metastatic to Bone 1 Prostate Adenocarcinoma 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Castrate-Resistant Prostate Cancer 1 Bone Metastatic Castration-resistant Prostate Cancer 1 Bone Metastases 1 Bone Diseases 1 Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Magnetic Resonance Spectroscopy 17 Iodine-131 16 lenvatinib 13 trametinib 12 Thyrotropin Alfa 11 Sorafenib 11 pembrolizumab 10 dabrafenib 10 Paclitaxel 9 vandetanib 8 Thyroxine 8 Surgical Procedures, Operative 7 Sunitinib 7 selpercatinib 6 cabozantinib 6 Nivolumab 6 Fluorodeoxyglucose F18 6 Everolimus 6 pazopanib 5 Vemurafenib 5 Thyroidectomy 5 Specimen Handling 5 Saline Solution 5 Radiotherapy 5 Radiofrequency Ablation 5 Cyclophosphamide 5 Cisplatin 5 Biopsy 5 apatinib 4 anlotinib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Thyroid Neoplasms × radium Ra 223 dichloride × Clear all

NCT02390934 2019-06-11

RAD-THYR

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡